Literature DB >> 16704440

Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q.

Rosario M Prieto-Sánchez1, José A Hernández, Juan L García, Norma C Gutiérrez, Jesús San Miguel, Xosé R Bustelo, Jesús M Hernández.   

Abstract

The expression of the VAV proto-oncogene in 57 patients with chronic myeloproliferative disease (CMD), B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin Lymphoma (B-NHL), and 61 with B-cell chronic lymphocytic leukaemia (B-CLL) was analysed. VAV overexpression was observed in 19.5% of cases and 81% of VAV-positive tumours also displayed VAV phosphorylation. Overexpression was not observed in B-ALL or CMD, but 13% of B-NHL and 34.4% of B-CLL patients (P = 0.002) overexpressed VAV. The overexpression and phosphorylation of VAV was detected more frequently in 13q- chronic lymphocytic leukaemias (71.4%) versus other B-CLLs (23.4%, P = 0.001). Overexpression of VAV protein is a frequent event in patients with B-CLL displaying loss of 13q sequences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16704440      PMCID: PMC1950221          DOI: 10.1111/j.1365-2141.2006.06094.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 2.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

3.  Vav mediates Ras stimulation by direct activation of the GDP/GTP exchange factor Ras GRP1.

Authors:  María J Caloca; José L Zugaza; David Matallanas; Piero Crespo; Xosé R Bustelo
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

4.  Global conformational rearrangements during the activation of the GDP/GTP exchange factor Vav3.

Authors:  Oscar Llorca; Ernesto Arias-Palomo; José L Zugaza; Xosé R Bustelo
Journal:  EMBO J       Date:  2005-03-10       Impact factor: 11.598

5.  Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo.

Authors:  J M Hernández; M B González; I Granada; N Gutiérrez; C Chillón; F Ramos; J M Ribera; M González; E Feliu; J San Miguel
Journal:  Haematologica       Date:  2000-05       Impact factor: 9.941

6.  Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.

Authors:  Martin E Fernandez-Zapico; Natalia C Gonzalez-Paz; Ellen Weiss; Doris N Savoy; Julian R Molina; Rafael Fonseca; Thomas C Smyrk; Suresh T Chari; Raul Urrutia; Daniel D Billadeau
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

7.  Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav.

Authors:  M López-Lago; H Lee; C Cruz; N Movilla; X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  A functional T-cell receptor signaling pathway is required for p95vav activity.

Authors:  J Wu; S Katzav; A Weiss
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

  8 in total
  15 in total

1.  Vav1 in hematologic neoplasms, a mini review.

Authors:  Matthew J Oberley; Deng-Shun Wang; David T Yang
Journal:  Am J Blood Res       Date:  2012-01-01

2.  The distinct role of guanine nucleotide exchange factor Vav1 in Bcl-2 transcription and apoptosis inhibition in Jurkat leukemia T cells.

Authors:  Jie Yin; Ya-juan Wan; Shi-yang Li; Ming-juan Du; Cui-zhu Zhang; Xing-long Zhou; You-jia Cao
Journal:  Acta Pharmacol Sin       Date:  2010-12-13       Impact factor: 6.150

3.  Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.

Authors:  Tamas Geczy; Megan L Peach; Saïd El Kazzouli; Dina M Sigano; Ji-Hye Kang; Christopher J Valle; Julia Selezneva; Wonhee Woo; Noemi Kedei; Nancy E Lewin; Susan H Garfield; Langston Lim; Poonam Mannan; Victor E Marquez; Peter M Blumberg
Journal:  J Biol Chem       Date:  2012-02-18       Impact factor: 5.157

4.  Structural basis of guanine nucleotide exchange mediated by the T-cell essential Vav1.

Authors:  Jill E Chrencik; Alexei Brooun; Hui Zhang; Irimpan I Mathews; Greg L Hura; Scott A Foster; J Jefferson P Perry; Markus Streiff; Paul Ramage; Hans Widmer; Gary M Bokoch; John A Tainer; Gisbert Weckbecker; Peter Kuhn
Journal:  J Mol Biol       Date:  2008-05-17       Impact factor: 5.469

5.  Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme.

Authors:  Juan Luis Garcia; Jose Couceiro; Juan Antonio Gomez-Moreta; J M Gonzalez Valero; Angel Santos Briz; Vincent Sauzeau; Eva Lumbreras; Manuel Delgado; Cristina Robledo; Monica Lara Almunia; Xose R Bustelo; Jesus M Hernandez
Journal:  J Neurooncol       Date:  2012-08-04       Impact factor: 4.130

Review 6.  Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease.

Authors:  D R Cook; K L Rossman; C J Der
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

Review 7.  Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.

Authors:  Shulamit Katzav
Journal:  Oncotarget       Date:  2015-10-06

8.  The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.

Authors:  Sergio Ruiz; Eugenio Santos; Xosé R Bustelo
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

9.  Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer.

Authors:  Shulamit Sebban; Marganit Farago; Dan Gashai; Lena Ilan; Eli Pikarsky; Ittai Ben-Porath; Shulamit Katzav
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Paxillin kinase linker (PKL) regulates Vav2 signaling during cell spreading and migration.

Authors:  Matthew C Jones; Kazuya Machida; Bruce J Mayer; Christopher E Turner
Journal:  Mol Biol Cell       Date:  2013-04-24       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.